Description: 23andMe, Inc., a consumer genetics and research company, engages in developing a genetic database to unlock insights leading to the rapid discovery of new targets for drug development. It offers a crowdsourced platform that helps people to access, understand, and benefit from the human genome; access direct-to-consumer genetic testing; and give consumers personalized information about their genetic health risks, ancestry, and traits. The company was incorporated in 2006 and is based in Sunnyvale, California with an additional office in Mountain View, California.
Home Page: www.23andme.com
ME Technical Analysis
349 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 938 6300
Officers
| Name | Title |
|---|---|
| Ms. Anne Wojcicki | Co-Founder, CEO, Pres & Director |
| Ms. Kathy L. Hibbs Esq., J.D. | Chief Admin. Officer and Sec. |
| Dr. Kenneth J. Hillan Ch.B., M.B. | Chief Therapeutics Officer |
| Mr. Joseph Selsavage | Interim CFO & Accounting Officer |
| Dr. Joseph R. Arron M.D., Ph.D. | Chief Scientific Officer |
| Dr. Wade Walke | VP of Investor Relations |
| Ms. Jacquie Cooke Haggarty J.D. | Gen. Counsel & Privacy Officer |
| Ms. Katie Watson | VP of Communications |
| Mr. Jonathan Ward | Chief Marketing Officer |
| Ms. Savita Pillai | VP of People |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7123 |
| Price-to-Sales TTM: | 4.1168 |
| IPO Date: | 2020-11-23 |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |